The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1741
November 10, 2025
View Complete Issue         Table of Contents 2019 
Garadacimab (Andembry) for Hereditary Angioedema Prophylaxis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Garadacimab (Andembry) for Hereditary Angioedema Prophylaxis
November 10, 2025 (Issue: 1741)
The FDA has approved garadacimab-gxii (Andembry – CSL Behring), a subcutaneously injected inhibitor of activated clotting factor XII, for prevention of hereditary angioedema (HAE) attacks in patients ≥12 years old. Garadacimab is the first...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Garadacimab (Andembry) for Hereditary Angioedema Prophylaxis
Article code: 1741c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.